首页> 外文期刊>Liver international >m5C and m6A modification of long noncoding NKILA accelerates cholangiocarcinoma progression via the miR‐582‐3p‐YAP1 axis
【24h】

m5C and m6A modification of long noncoding NKILA accelerates cholangiocarcinoma progression via the miR‐582‐3p‐YAP1 axis

机译:m5C and m6A modification of long noncoding NKILA accelerates cholangiocarcinoma progression via the miR‐582‐3p‐YAP1 axis

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Cholangiocarcinoma (CCA) is a severe malignancy originating from the bile duct and the second most common primary liver cancer. NF‐kappa B interacting lncRNA (NKILA) is a functional lncRNA, which play important role in human cancers. However, the role and underlying mechanism of NKILA in CCA remains largely unknown. Here, our study demonstrated that NKILA was significantly upregulated in CCA tissues and cells. Overexpression of NKILA is associated with advanced TNM stage, lymph node and distant metastasis, and also indicated poor prognosis in CCA patients. Functionally, NKILA facilitated CCA growth and metastasis in vitro and in vivo. The 5‐methylcytosine (m5C) methyltransferase NSUN2 interacts with NKILA, increasing its m5C level and promoting its interaction with YBX1. Moreover, NKILA physically interacted with and suppressed miR‐582‐3p, which was regulated by METTL3‐mediated N6‐methyladenosine (m6A) modification. Finally, we showed that YAP1 was a target of NKILA via miR‐582‐3p and NKILA functioned partially via YAP1 in CCA. Taken together, our findings indicate a novel regulatory mechanism of NKILA for promoting CCA progression and that NKILA may be a promising target for CCA treatment.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号